All News
![](https://pbs.twimg.com/media/GE4fhJCWgAAMpXx.jpg)
When should you intervene? We talk about primary and secondary prevention... but what about primordial prevention that targets social determinants of health? - @drdavidkarp #RNL2024 @rheumnow https://t.co/UGAcNFLqZf
TheDaoIndex KDAO2011 ( View Tweet)
![](https://pbs.twimg.com/media/GE4ghgIW4AAUTZr.jpg)
What early biomarkers are specific for SLE? How many will progress to stage 2? Who should we screen? Will patients revert to pre-stage 1? Is progression preventable? @DrDavidKarp on relevant questions we need to ask regarding preclinical stage 1 lupus. #RNL2024 @rheumnow https://t.co/bJPG68WdyE
TheDaoIndex KDAO2011 ( View Tweet)
![](https://pbs.twimg.com/media/GE4hEhcXEAEAkGN.jpg)
Can HCQ prevent SLE? Results of the MONA-LISA study is being analyzed (pts have +ANA and 1-2 SLICC criteria for SLE randomized to PCB or HCQ) - @DrDavidKarp @rheumnow #RNL2024 https://t.co/9yoFXS7wMe
TheDaoIndex KDAO2011 ( View Tweet)
![](https://pbs.twimg.com/media/GE4hMzzWgAAU7nr.png)
#RNL2024 @RheumNow
@DrDavidKarp
Incomplete lupus is heterogeneous term
"Stage 2" pre-classification stage as ILE/UCTD
Stage 1: non-specific antibodies, dysregulation
2: incomplete features
3: classified, multi-system disease
4: irreversible tissue damage https://t.co/CuLUzSZ24E
Links:
Eric Dein ericdeinmd ( View Tweet)
![](https://pbs.twimg.com/media/GE4cLb8XgAAm3ti.jpg)
@reumacia @RheumNow You are absolutely right. The point was not generally used for psoriasis ( not PsA). I was surprised my self 🤕.
Here is the slide again by Dr. Armstrong , great talk by the way. Let me know if you want the handout. https://t.co/C11Gkn2jho
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
![](https://pbs.twimg.com/media/GE4YoyvXgAE-la1.jpg)
Appreciative inquiry in rheumatology and how to enhance and improve our clinical notes to frame our encounter in a positive manner.
@BharatKumarMD
#RNL2024
@RheumNow https://t.co/iTXwjUb6tg
Links:
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
![](https://pbs.twimg.com/media/GE4Xh2-XAAEBWpP.jpg)
Some takeways from JAK inhibitors in dermatology talk by Bruce Strober.
Great talk.
#RNL2024
@RheumNow https://t.co/fuRsSnnsha
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
![](https://pbs.twimg.com/media/GE4XMyiXUAEI7hA.jpg)
Alopecia aerate and JAK
Bruce Strober
#RNL2024
@RheumNow https://t.co/lGig1Vpf5x
Links:
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
![](https://pbs.twimg.com/media/GE4W_G0WkAAsSvj.jpg)
Examples from the world of dermatology on JAK inhibitor success stories.
Bruce storber.
#RNL2024
@RheumNow https://t.co/S01lEIqjbR
Links:
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
![](https://pbs.twimg.com/media/GE4Wdb-XQAANuft.jpg)
Dermatology colleagues are using JAKis with success for wide range of dermatological diseases.
Note the beauty of this slide with further elaboration on domain inhibition, cool stuff 🤓
Bruce Strober
#RNL2024
@RheumNow https://t.co/2yHHcOgTC8
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
![](https://pbs.twimg.com/media/GE4VyfyXgAAe7wA.jpg)
Allosteric versus active site inhibition by JAK.
Never understood this better.
Thanks to Bruce Strober.
#RNL2024
@RheumNow https://t.co/r9hhHLO5oS
Links:
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
![](https://pbs.twimg.com/media/GE4U6rwWcAI3zg8.jpg)
JAK safety and malignancy risk.
Great talk by kevin Winthrop.
#RNL2024
@RheumNow https://t.co/d7WRHJxrpM
Links:
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
![](https://pbs.twimg.com/media/GE4UGB6X0AANal7.png)
@BharatKumarMD at #RNL2024 @RheumNow
Appreciative Inquiry in Rheumatology
5(ish) steps
Dawn (what focus on) -> Discovery (what gives life) -> Dream (what might be) -> Design (what should be) -> Destiny (how can i execute) -> New Dawn
- Empathy at center of inquiry https://t.co/gDhXpi94pT
Eric Dein ericdeinmd ( View Tweet)
![](https://pbs.twimg.com/media/GE4UBytW8AEcm0W.jpg)
JAK toxicity of interest.
Eric Ruderman
#RNL2024
@RheumNow https://t.co/qdlJFKTUR8
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
![](https://pbs.twimg.com/media/GE4T1D-XgAAc5Gg.jpg)
Unique and selective allosteric mechanism of deucravacitinib.
Eric Ruderman
#RNL2024
@RheumNow https://t.co/Zm3bYGR9JJ
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
![](https://pbs.twimg.com/media/GE302TEXsAI5k59.jpg)
Disease activity indices may perform differently in man and women.
@lihi_eder
#RNL2024
@RheumNow https://t.co/8G1D0pGKe8
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
![](https://pbs.twimg.com/media/GE31SmPXsAASeMo.jpg)
Diagnostic delay in SpA
2.3 years longer delay in diagnosis in women with PsA.
@lihi_eder
#RNL2024
@RheumNow https://t.co/d9ao8vvpa5
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
![](https://pbs.twimg.com/media/GE4FkUtXoAAMW8q.jpg)
I am jealous of the derms who have topical JAKi!
Dr. Strober flaunts all the different JAKi he has at his disposal to treat derm diseases #RNL2024 @rheumnow https://t.co/qdMWCSA5I1
TheDaoIndex KDAO2011 ( View Tweet)
![](https://pbs.twimg.com/media/GE4TQiYW8AEyAr6.jpg)
JAK and TYK2 signaling pathways.
Eric Ruderman
#RNL2024
@RheumNow https://t.co/WxoZGCEL0z
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
![](https://pbs.twimg.com/media/GE4Sxj7W0AAGf8o.jpg)
JAKinib negatives.
Eric Ruderman
#RNL2024
@RheumNow https://t.co/vVzSQMVa5a
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)